PhaseBio Pharmaceuticals, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PHAS research report →
Companyphasebio.com
PhaseBio Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiovascular diseases. Its lead product candidate is bentracimab (PB2452), a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients with uncontrolled major or life-threatening bleeding events or in patients requiring urgent or an invasive procedure.
- CEO
- Jonathan Mow
- IPO
- 2018
- Employees
- 60
- HQ
- Malvern, PA, US
Price Chart
Valuation
- Market Cap
- $0
- P/E
- -15.72
- P/S
- 0.00
- P/B
- -0.02
- EV/EBITDA
- -20.42
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 100.00%
- Op Margin
- -1204.12%
- Net Margin
- -1210.15%
- ROE
- 0.22%
- ROIC
- -0.34%
Growth & Income
- Revenue
- $10.83K · -96.62%
- Net Income
- $-131,071 · 99.87%
- EPS
- $-0.00 · 99.87%
- Op Income
- $-130,418
- FCF YoY
- 18.37%
Performance & Tape
- 52W High
- $4.08
- 52W Low
- $0.04
- 50D MA
- $0.43
- 200D MA
- $0.91
- Beta
- 2.87
- Avg Volume
- 1.79M
Get TickerSpark's AI analysis on PHAS
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 19, 23 | van den Broek Richard | other | 3,750 |
| May 19, 23 | van den Broek Richard | other | 3,750 |
| May 19, 23 | Thorp Clay | other | 3,750 |
| May 19, 23 | Thorp Clay | other | 3,750 |
| May 19, 23 | Humphries William D. | other | 2,538 |
| May 19, 23 | Humphries William D. | other | 2,538 |
| May 19, 23 | HARRIGAN EDMUND | other | 3,750 |
| May 19, 23 | HARRIGAN EDMUND | other | 3,750 |
| May 19, 23 | Sapir Alex | other | 3,750 |
| May 19, 23 | Sapir Alex | other | 3,750 |
Our PHAS Coverage
We haven't published any research on PHAS yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate PHAS Report →